MPM BioImpact’s Harmony Biosciences HRMY Stock Holding History

MPM BioImpact’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-139,377	Closed	-$7.68M	–	32
2022 Q4	$7.68M	Buy	139,377 +2,597	+2%	+$143K	1.99%	15
2022 Q3	$6.06M	Sell	136,780 -737	-0.5%	-$36K	1.43%	20
2022 Q2	$6.71M	Hold	137,517	–	–	1.86%	16
2022 Q1	$6.69M	Sell	137,517 -4,920	-3%	-$201K	1.8%	15
2021 Q4	$6.07M	Sell	142,437 -9,213	-6%	-$367K	1.11%	23
2021 Q3	$5.81M	Buy	+151,650	New	+$4.88M	0.9%	24

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

MPM BioImpact's HRMY Position: Q1 2023 in Review

MPM BioImpact sold out of Harmony Biosciences (HRMY) in Q1 2023, closing a stake of 139,377 shares — an estimated $7.68M sold.

MPM BioImpact first reported a position in HRMY in Q3 2021 and held it in 6 quarters. The position peaked at $7.68M in Q4 2022. 217 funds tracked by Wall St. Rank hold HRMY as of Q1 2023.

MPM BioImpact reported no remaining Harmony Biosciences position as of Q1 2023 after selling out during the quarter.
MPM BioImpact sold 139,377 Harmony Biosciences shares in Q1 2023, an estimated $7.68M.
MPM BioImpact first reported a position in Harmony Biosciences in Q3 2021 and held it in 6 quarters.
MPM BioImpact's Harmony Biosciences position peaked at $7.68M in Q4 2022.
217 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2023.

Based on MPM BioImpact's 13F filing for Q1 2023, filed 12 May 2023.